New MIT research reveals triple-combination adhesive patch prevent recurrence of colorectal cancer
New studies made by researchers at the Cambridge, Massachusetts-based Massachusetts Institute of Technology made the public know of an adhesive patch that can give colorectal tumors a triple-combination of drug, gene, and light-based therapy.
Statistics show that the lifetime risk of developing colorectal cancer for men is around 1 in 21 and around 1 in 23 or women in the United States. Colorectal cancers make their start as a growth or a tumor on the inner lining of the colon or rectum, developing into cancer within 10 to 15 years.
Undergoing an operation sometimes doesn’t equate to the complete removal of the cancerous growths; this is particularly dangerous because the cancer growths can spread to other organs and can lead to the development of cancer in other organs.
However, this new triple-therapy hydrogel patch can be used to ensure that the remaining cells at the tumor site after surgery will not result in recurrence of cancer and will prevent the cancer cells from going to other organs, MIT’s Institute for Medical Engineering and Science research scientist and Boston-based Brigham and Women’s Hospital assistant professor of medicine Natalie Artzi said.
Our attorneys at Crowe & Mulvey, LLP, who provide legal services to our clients in the state of Massachusetts, handle medical malpractice cases such as failure to diagnose cancer, wrongful death, hospital negligence, surgical and medication errors, improper emergency room treatment, among others. Call our offices today at (617) 426-4488.